David Duvall v. Novant Health, Inc.

95 F.4th 778
CourtCourt of Appeals for the Fourth Circuit
DecidedMarch 12, 2024
Docket22-2142
StatusPublished
Cited by6 cases

This text of 95 F.4th 778 (David Duvall v. Novant Health, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Fourth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
David Duvall v. Novant Health, Inc., 95 F.4th 778 (4th Cir. 2024).

Opinion

USCA4 Appeal: 22-2142 Doc: 55 Filed: 03/12/2024 Pg: 1 of 30

PUBLISHED

UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT

No. 22-2142

DAVID L. DUVALL,

Plaintiff – Appellee,

v.

NOVANT HEALTH, INC.,

Defendant – Appellant.

Appeal from the United States District Court for the Western District of North Carolina, at Charlotte. David Shepardson Cayer, Magistrate Judge. (3:19-cv-00624-DSC)

Argued: December 7, 2023 Decided: March 12, 2024

Before AGEE and QUATTLEBAUM, Circuit Judges, and FLOYD, Senior Circuit Judge.

Affirmed in part, vacated in part, and remanded with instructions by published opinion. Judge Agee wrote the opinion in which Judge Quattlebaum and Senior Judge Floyd joined.

ARGUED: Stephen Montgomery Cox, ROBINSON, BRADSHAW & HINSON, PA, Rock Hill, South Carolina, for Appellant. S. Luke Largess, TIN FULTON WALKER & OWEN, Charlotte, North Carolina, for Appellee. ON BRIEF: Charles E. Johnson, Angelique R. Vincent-Hamacher, Travis S. Hinman, ROBINSON, BRADSHAW & HINSON, P.A., Charlotte, North Carolina; Benjamin R. Holland, Margaret Santen Hanrahan, OGLETREE, DEAKINS, NASH, SMOAK & STEWART, P.C., Charlotte, North Carolina, for Appellant. USCA4 Appeal: 22-2142 Doc: 55 Filed: 03/12/2024 Pg: 2 of 30

AGEE, Circuit Judge:

After a week-long trial, a North Carolina jury found that Novant Health, Inc.

terminated David Duvall because of his race, sex, or both, in violation of Title VII of the

Civil Rights Act of 1964, 42 U.S.C. §§ 2000e to 2000e–17. In addition to the finding of

liability, the jury awarded Duvall $10 million in punitive damages. Novant Health moved

under Federal Rule of Civil Procedure 50(b) for judgment as a matter of law and to set

aside the punitive damages award, arguing that the evidence adduced at trial was

insufficient to support the jury’s verdict. It also opposed Duvall’s competing motion for

back pay and front pay, claiming that he failed to mitigate his damages. Following a

hearing, the district court denied Novant Health’s motion for judgment as a matter of law;

granted in part and denied in part Novant Health’s motion to set aside the jury’s award of

punitive damages, reducing the award to the statutory maximum of $300,000 but otherwise

finding punitive damages appropriate; and granted Duvall’s motion for back pay and front

pay. Novant Health now appeals.

After a careful review of the record, we hold that sufficient evidence was presented

at trial to sustain the jury’s finding of liability but not its award of punitive damages. We

also find that the district court did not abuse its discretion in awarding Duvall back pay and

front pay. Accordingly, we affirm in part, vacate in part, and remand for entry of an

amended judgment consistent with this opinion.

2 USCA4 Appeal: 22-2142 Doc: 55 Filed: 03/12/2024 Pg: 3 of 30

I.

A. 1

Duvall, a white man, began working for Novant Health in 2013, when Executive

Vice President and Chief Consumer Officer Jesse Cureton, a black man, hired him as

Senior Vice President of Marketing and Communications. Based in North Carolina, Duvall

reported directly to Cureton and held the same position throughout his employment with

Novant Health. Evidence presented at trial demonstrated that Duvall performed

exceptionally in his role, receiving strong performance reviews and gaining national

recognition for himself and the marketing program he developed for Novant Health.

Despite all that, Cureton fired Duvall in July 2018, a decision that came as a shock to both

Duvall and his colleagues. Moreover, Novant Health—a multibillion-dollar company with

tens of thousands of employees and an extensive human resources department—had no

record of any documented criticism of Duvall’s performance or reasons for his termination.

Immediately after firing Duvall, Novant Health elevated two of Duvall’s deputies,

a white woman and a black woman, to take over his duties. It then later hired another black

woman to permanently replace Duvall.

Believing Novant Health fired him merely to achieve racial and gender diversity—

or more specifically, to hit certain diversity “targets,” J.A. 1431—within its leadership,

1 We accept and recite the facts in the light most favorable to the nonmoving party, Duvall, as we must in reviewing a post-trial Rule 50(b) ruling. First Union Com. Corp. v. GATX Cap. Corp., 411 F.3d 551, 556 (4th Cir. 2005).

3 USCA4 Appeal: 22-2142 Doc: 55 Filed: 03/12/2024 Pg: 4 of 30

Duvall sued his former employer under Title VII and North Carolina state law in federal

district court. The case proceeded to trial, where a jury heard the following evidence.

1.

In 2015, Novant Health President and Chief Executive Officer (“CEO”) Carl

Armato appointed Tanya Blackmon as Senior Vice President of Diversity and Inclusion

(“D&I”) to develop a “Diversity and Inclusion Strategic Plan” for Novant Health (the “D&I

Plan”). J.A. 1365–78. That D&I Plan, which Novant Health’s Executive Team 2 approved,

consisted of three phases: Phase 1 (“Learn and Engage”) would assess Novant Health’s

D&I culture, benchmark its D&I levels, and seek to get Novant Health’s Board and

leadership to commit to using D&I in decision-making. J.A. 1365. Phase 2 (“Develop and

Influence”) would set goals to “embed diversity and inclusion” in three to five years, with

a commitment to “adding additional dimensions of diversity to the executive and senior

leadership teams” and establishing “a system wide decision making process that includes

a diversity and inclusion lens.” J.A. 1365–66. And Phase 3 (“Leverage”) would evaluate

the progress toward embedding D&I and “implement strategies and tactics to close

identified gaps.” J.A. 1368.

In November 2016, Blackmon, who had since been promoted to Executive Vice

President and Chief Diversity and Inclusion Officer, presented a “Business Case” for the

D&I Plan to Novant Health’s Board. J.A. 160, 1327–64. That presentation established a

2 The Executive Team consisted of “the president and CEO and executive vice presidents of the company.” J.A. 242.

4 USCA4 Appeal: 22-2142 Doc: 55 Filed: 03/12/2024 Pg: 5 of 30

timeline to develop D&I metrics and “[i]ntentionally integrate” D&I in 2017; to evaluate

those metrics and Novant Health’s use of a “[D&I] lens” in decision-making in 2018; and

to fully “embed[]” D&I by 2019. J.A. 1364. Novant Health’s Board approved the Business

Case and its D&I Plan timeline.

In February 2018, Novant Health’s Diversity and Inclusion Executive Council

(“D&I Council”), the body responsible for overseeing and implementing the D&I Plan

and whose members included Blackmon, Cureton, and Duvall, held its first meeting. At

that meeting, the D&I Council discussed various models for measuring the success of

Novant Health’s D&I efforts.

The D&I Council next met in May 2018 and continued its discussion of D&I

metrics. In doing so, the council reviewed demographic data on Novant Health’s workforce

and leadership, which showed a decline in female leaders from 2015 to 2017 (except on

the Executive Team). It also showed that while 82 percent of Novant Health’s workforce

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
95 F.4th 778, Counsel Stack Legal Research, https://law.counselstack.com/opinion/david-duvall-v-novant-health-inc-ca4-2024.